Galectin Therapeutics Inc.
NASDAQ:GALT
Overview | Financials
Company Name | Galectin Therapeutics Inc. |
Symbol | GALT |
Currency | USD |
Price | 1.15 |
Market Cap | 71,654,315 |
Dividend Yield | 0% |
52-week-range | 0.73 - 4.27 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Joel Lewis |
Website | https://galectintherapeutics.com |
An error occurred while fetching data.
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD